BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Paolisso P, Bergamaschi L, Santulli G, Gallinoro E, Cesaro A, Gragnano F, Sardu C, Mileva N, Foà A, Armillotta M, Sansonetti A, Amicone S, Impellizzeri A, Casella G, Mauro C, Vassilev D, Marfella R, Calabrò P, Barbato E, Pizzi C. Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry. Cardiovasc Diabetol 2022;21:77. [PMID: 35570280 DOI: 10.1186/s12933-022-01506-8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 28.0] [Reference Citation Analysis]
Number Citing Articles
1 Mone P, Lombardi A, Salemme L, Cioppa A, Popusoi G, Varzideh F, Pansini A, Jankauskas SS, Forzano I, Avvisato R, Wang X, Tesorio T, Santulli G. Stress Hyperglycemia Drives the Risk of Hospitalization for Chest Pain in Patients With Ischemia and Nonobstructive Coronary Arteries (INOCA). Diabetes Care 2023;46:450-4. [PMID: 36478189 DOI: 10.2337/dc22-0783] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
2 Chen S, Wang Q, Christodoulou A, Mylonas N, Bakker D, Nederlof R, Hollmann MW, Weber NC, Coronel R, Wakker V, Christoffels VM, Andreadou I, Zuurbier CJ. Sodium Glucose Cotransporter-2 Inhibitor Empagliflozin Reduces Infarct Size Independently of Sodium Glucose Cotransporter-2. Circulation 2023;147:276-9. [PMID: 36649392 DOI: 10.1161/CIRCULATIONAHA.122.061688] [Reference Citation Analysis]
3 Paolisso P, Bergamaschi L, Gragnano F, Gallinoro E, Cesaro A, Sardu C, Mileva N, Foà A, Armillotta M, Sansonetti A, Amicone S, Impellizzeri A, Esposito G, Morici N, Andrea OJ, Casella G, Mauro C, Vassilev D, Galie N, Santulli G, Marfella R, Calabrò P, Barbato E, Pizzi C. Reply to SGLT-2 inhibitors: Post-infarction interventional effects. Pharmacol Res 2023;:106664. [PMID: 36642618 DOI: 10.1016/j.phrs.2023.106664] [Reference Citation Analysis]
4 Sardu C, Santulli G, Savarese G, Trotta MC, Sacra C, Santamaria M, Volpicelli M, Ruocco A, Mauro C, Signoriello G, Marfella L, D'Amico M, Marfella R, Paolisso G. Endothelial Dysfunction Drives CRTd Outcome at 1-Year Follow-Up: A Novel Role as Biomarker for miR-130a-5p. Int J Mol Sci 2023;24:1510. [PMID: 36675028 DOI: 10.3390/ijms24021510] [Reference Citation Analysis]
5 Zhou Y, Song X, Ma J, Wang X, Fu H. Association of inflammation indices with left atrial thrombus in patients with valvular atrial fibrillation. BMC Cardiovasc Disord 2023;23:9. [PMID: 36624370 DOI: 10.1186/s12872-023-03036-x] [Reference Citation Analysis]
6 Rachwalik M, Matusiewicz M, Jasiński M, Hurkacz M. Evaluation of the usefulness of determining the level of selected inflammatory biomarkers and resistin concentration in perivascular adipose tissue and plasma for predicting postoperative atrial fibrillation in patients who underwent myocardial revascularisation. Lipids Health Dis 2023;22:2. [PMID: 36624488 DOI: 10.1186/s12944-022-01769-w] [Reference Citation Analysis]
7 Paolisso P, Bergamaschi L, Gragnano F, Gallinoro E, Cesaro A, Sardu C, Mileva N, Foà A, Armillotta M, Sansonetti A, Amicone S, Impellizzeri A, Esposito G, Nuccia M, Andrea OJ, Casella G, Mauro C, Vassilev D, Galie N, Santulli G, Marfella R, Calabrò P, Pizzi C, Barbato E. Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry. Pharmacol Res 2023;187:106597. [PMID: 36470546 DOI: 10.1016/j.phrs.2022.106597] [Reference Citation Analysis]
8 Patoulias D, Katsimardou A, Fragakis N, Papadopoulos C, Doumas M. Effect of SGLT-2 inhibitors on cardiac autonomic function in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Acta Diabetol 2023;60:1-8. [PMID: 35986116 DOI: 10.1007/s00592-022-01958-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Mone P, Lombardi A, Kansakar U, Varzideh F, Jankauskas SS, Pansini A, Marzocco S, De Gennaro S, Famiglietti M, Macina G, Frullone S, Santulli G. Empagliflozin Improves the MicroRNA Signature of Endothelial Dysfunction in Patients with Heart Failure with Preserved Ejection Fraction and Diabetes. J Pharmacol Exp Ther 2023;384:116-22. [PMID: 36549862 DOI: 10.1124/jpet.121.001251] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
10 Arenal Á, Ríos-Muñoz GR, Carta-Bergaz A, Ruiz-Hernández PM, Pérez-David E, Crisóstomo V, Loughlin G, Sanz-Ruiz R, Fernández-Portales J, Acosta A, Báez-Díaz C, Blanco-Blázquez V, Ledesma-Carbayo MJ, Pareja M, Fernández-Santos ME, Sánchez-Margallo FM, Casado JG, Fernández-Avilés F. Effects of Cardiac Stem Cell on Postinfarction Arrhythmogenic Substrate. Int J Mol Sci 2022;23. [PMID: 36555857 DOI: 10.3390/ijms232416211] [Reference Citation Analysis]
11 Kowalska K, Wilczopolski P, Buławska D, Młynarska E, Rysz J, Franczyk B. The Importance of SGLT-2 Inhibitors as Both the Prevention and the Treatment of Diabetic Cardiomyopathy. Antioxidants (Basel) 2022;11. [PMID: 36552708 DOI: 10.3390/antiox11122500] [Reference Citation Analysis]
12 Donniacuo M, De Angelis A, Telesca M, Bellocchio G, Riemma MA, Paolisso P, Scisciola L, Cianflone E, Torella D, Castaldo G, Capuano A, Urbanek K, Berrino L, Rossi F, Cappetta D. Atrial fibrillation: Epigenetic aspects and role of sodium-glucose cotransporter 2 inhibitors. Pharmacol Res 2022;188:106591. [PMID: 36502999 DOI: 10.1016/j.phrs.2022.106591] [Reference Citation Analysis]
13 Ramani J, Shah H, Vyas VK, Sharma M. A review on the medicinal chemistry of sodium glucose co-transporter 2 inhibitors (SGLT2-I): Update from 2010 to present. European Journal of Medicinal Chemistry Reports 2022;6:100074. [DOI: 10.1016/j.ejmcr.2022.100074] [Reference Citation Analysis]
14 Scisciola L, Taktaz F, Fontanella RA, Pesapane A, Surina S, Cataldo V, Ghosh P, Franzese M, Puocci A, Paolisso P, Rafaniello C, Marfella R, Rizzo MR, Barbato E, Vanderheyden M, Barbieri M. Targeting High Glucose-Induced Epigenetic Modifications at Cardiac Levels: The Role of SGLT2 and SGLT2 Inhibitors.. [DOI: 10.21203/rs.3.rs-2300456/v1] [Reference Citation Analysis]
15 Katsiki N, Kazakos K, Triposkiadis F. Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes. Expert Opinion on Pharmacotherapy 2022. [DOI: 10.1080/14656566.2022.2143263] [Reference Citation Analysis]
16 Wang D, Liu J, Zhong L, Li S, Zhou L, Zhang Q, Li M, Xiao X. The effect of sodium-glucose cotransporter 2 inhibitors on biomarkers of inflammation: A systematic review and meta-analysis of randomized controlled trials. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.1045235] [Reference Citation Analysis]
17 Capuano A, Clementi E, Paolisso G. Editorial: Clinical prospective of SGLT2 inhibitors in atherosclerosis. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.1040649] [Reference Citation Analysis]
18 Zhang J, Zhang F, Ge J. SGLT2 inhibitors protect cardiomyocytes from myocardial infarction: a direct mechanism? Future Cardiol 2022;18:867-82. [PMID: 36111579 DOI: 10.2217/fca-2022-0058] [Reference Citation Analysis]
19 Wang Q, Wang J, Ma Y, Wang P, Li Y, Tian J, Yue X, Su G, Li B. Predictive value of myocardial strain on myocardial infarction size by cardiac magnetic resonance imaging in ST-segment elevation myocardial infarction with preserved left ventricular ejection fraction. Front Pharmacol 2022;13:1015390. [DOI: 10.3389/fphar.2022.1015390] [Reference Citation Analysis]
20 Karalliedde J, Fountoulakis N, Stathi D, Corcillo A, Flaquer M, Panagiotou A, Maltese G, Mangelis A, Ayis S, Gnudi L. Does Dapagliflozin influence arterial stiffness and levels of circulating anti-aging hormone soluble Klotho in people with type 2 diabetes and kidney disease? Results of a randomized parallel group clinical trial. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.992327] [Reference Citation Analysis]
21 Cesaro A, Gragnano F, Paolisso P, Bergamaschi L, Gallinoro E, Sardu C, Mileva N, Foà A, Armillotta M, Sansonetti A, Amicone S, Impellizzeri A, Esposito G, Morici N, Oreglia JA, Casella G, Mauro C, Vassilev D, Galie N, Santulli G, Pizzi C, Barbato E, Calabrò P, Marfella R. In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study. Front Cardiovasc Med 2022;9:1012220. [PMID: 36237914 DOI: 10.3389/fcvm.2022.1012220] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
22 Mascolo A, Di Napoli R, Balzano N, Cappetta D, Urbanek K, De Angelis A, Scisciola L, Di Meo I, Sullo MG, Rafaniello C, Sportiello L. Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.1010693] [Reference Citation Analysis]
23 Tanaka A, Imai T, Shimabukuro M, Nakamura I, Matsunaga K, Ozaki Y, Minamino T, Sata M, Node K; CANDLE trial investigators. Effect of canagliflozin on white blood cell counts in patients with type 2 diabetes and heart failure: A subanalysis of the randomized CANDLE trial. J of Diabetes Invest. [DOI: 10.1111/jdi.13899] [Reference Citation Analysis]
24 Marfella R, Scisciola L, D'Onofrio N, Maiello C, Trotta MC, Sardu C, Panarese I, Ferraraccio F, Capuano A, Barbieri M, Balestrieri ML, Napoli C, Paolisso G. Sodium-glucose cotransporter-2 (SGLT2) expression in diabetic and non-diabetic failing human cardiomyocytes. Pharmacol Res 2022;184:106448. [PMID: 36096423 DOI: 10.1016/j.phrs.2022.106448] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
25 Gliozzi M, Macrì R, Coppoletta AR, Musolino V, Carresi C, Scicchitano M, Bosco F, Guarnieri L, Cardamone A, Ruga S, Scarano F, Nucera S, Mollace R, Bava I, Caminiti R, Serra M, Maiuolo J, Palma E, Mollace V. From Diabetes Care to Heart Failure Management: A Potential Therapeutic Approach Combining SGLT2 Inhibitors and Plant Extracts. Nutrients 2022;14:3737. [PMID: 36145112 DOI: 10.3390/nu14183737] [Reference Citation Analysis]
26 Blanks AM, Pedersen LN, Caslin HL, Mihalick VL, Via J, Canada JM, Van Tassell B, Carbone S, Abbate A, Lee Franco R. LPS differentially affects expression of CD14 and CCR2 in monocyte subsets of Post-STEMI patients with hyperglycemia. Diabetes Res Clin Pract 2022;191:110077. [PMID: 36089102 DOI: 10.1016/j.diabres.2022.110077] [Reference Citation Analysis]
27 Scisciola L, Cataldo V, Taktaz F, Fontanella RA, Pesapane A, Ghosh P, Franzese M, Puocci A, De Angelis A, Sportiello L, Marfella R, Barbieri M. Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: Data from basic science and clinical trials. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.1008922] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
28 Avogaro A, de Kreutzenberg SV, Morieri ML, Fadini GP, Del Prato S. Glucose-lowering drugs with cardiovascular benefits as modifiers of critical elements of the human life history. The Lancet Diabetes & Endocrinology 2022. [DOI: 10.1016/s2213-8587(22)00247-9] [Reference Citation Analysis]
29 Chou OHI, Ning J, Chiu Chan RN, Chung CT, Huang H, Ng K, Dee EC, Lee S, Kaewdech A, Liu T, Jing F, Yung Cheung BM, Tse G, Zhou J. Lower risks of sodium glucose cotransporter 2 (SGLT2) inhibitors compared to dipeptidyl peptidase-4 (DPP4) inhibitors for new-onset non-alcoholic fatty liver disease and hepatocellular carcinoma in type 2 diabetes mellitus: A population-based study.. [DOI: 10.1101/2022.08.16.22278847] [Reference Citation Analysis]
30 Wu YJ, Wang SB, Wang LS. SGLT2 Inhibitors: New Hope for the Treatment of Acute Myocardial Infarction? Am J Cardiovasc Drugs 2022. [PMID: 35947249 DOI: 10.1007/s40256-022-00545-6] [Reference Citation Analysis]
31 Mone P, Varzideh F, Jankauskas SS, Pansini A, Lombardi A, Frullone S, Santulli G. SGLT2 Inhibition via Empagliflozin Improves Endothelial Function and Reduces Mitochondrial Oxidative Stress: Insights From Frail Hypertensive and Diabetic Patients. Hypertension 2022;79:1633-43. [PMID: 35703100 DOI: 10.1161/HYPERTENSIONAHA.122.19586] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 18.0] [Reference Citation Analysis]
32 Wang D, Zhang C, Yang Y, He S, Zhu P, Chen X, Chiefari E. Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Urine Albumin to Creatinine Ratio in Type 2 Diabetes Mellitus Patients and Medication Care. Journal of Diabetes Research 2022;2022:1-8. [DOI: 10.1155/2022/5854200] [Reference Citation Analysis]
33 Kurczyński D, Hudzik B, Jagosz M, Zabierowski J, Nowak J, Tomasik A, Badziński A, Rozentryt P, Gąsior M. Sodium-Glucose Cotransporter-2 Inhibitors-from the Treatment of Diabetes to Therapy of Chronic Heart Failure. JCDD 2022;9:225. [DOI: 10.3390/jcdd9070225] [Reference Citation Analysis]